ClinicalTrials.gg
CompletedNCT02034578Updated Jul 20, 2016Results posted

Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects

A Phase 1 interventional study of Apixaban in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-07-20.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to assess the bioavailability of Apixaban solution administered through NGT and washed with Dextrose 5% in water (D5W) or infant formula relative to Apixaban solution administered orally in healthy subjects

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects as determined by no deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness
  • Any history or evidence of abnormal bleeding or coagulation disorders, intracranial hemorrhage, or abnormal bleeding (including heavy menstrual bleeding that has resulted in anemia within the past 1 year) or coagulation disorders in a first degree relative
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Arm A: Apixaban

    Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via oral syringe

    Drug: Apixaban

  • Experimental
    Arm B: Apixaban

    Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via nasogastric tube (NGT) immediately followed by 60 mL of D5W via NGT

    Drug: Apixaban

  • Experimental
    Arm C: Apixaban

    Single dose Apixaban 5 mg (0.4 mg/mL x 12.5 mL) oral solution via NGT immediately followed by 60 mL of infant formula via NGT

    Drug: Apixaban

Interventions

06

What researchers measure

Primary outcomes

  1. Adjusted Geometric Mean Maximum Observed Plasma Concentration (Cmax) of Apixaban

    Samples of plasma from participants were obtained at the following times: 0 hour (h) and post dose at 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h. Apixaban was assayed using a validated Liquid chromatography tandem mass spectrometry (LC-MS/MS) method during the period of known analyte stability. Maximum observed plasma concentration (Cmax) was measured in nanograms per milliliter (ng/mL).

    Time frame: Day 1 (0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h post dose) in Periods 1, 2 and 3

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs, Death

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

    Time frame: Day 1 to Day 12

  2. Median Time of Maximum Observed Plasma Concentration (Tmax) of Apixaban

    Samples of plasma from participants were obtained at the following times: 0 hour (h), 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h, relative to the single dose on Day 1 in each cross over period. Apixaban was assayed using a validated LC-MS/MS method during the period of known analyte stability. Maximum observed plasma concentration (Tmax) was measured in hours (h).

    Time frame: Day 1 (0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h post dose) in Periods 1, 2 and 3

  3. Adjusted Geometric Mean Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of Last Quantifiable Plasma Concentration, AUC(0-T), of Apixaban

    Samples of plasma from participants were obtained at the following times: 0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h, relative to the single dose on Day 1 in each cross over period. Apixaban was assayed using a validated LC-MS/MS method during the period of known analyte stability. AUC(0-T) was measured in nanograms\*hours per milliliter (ng\*h/mL).

    Time frame: Day 1 (0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h post dose) in Periods 1, 2 and 3

  4. Adjusted Geometric Mean Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time, AUC(INF), of Apixaban

    Samples of plasma from participants were obtained at the following times: 0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h, relative to the single dose on Day 1 in each cross over period. Apixaban was assayed using a validated LC-MS/MS method during the period of known analyte stability. AUC(0-INF) was measured in ng\*h/mL.

    Time frame: Day 1 (0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h post dose) in Periods 1, 2 and 3

  5. Mean Plasma Elimination Half-Life (T-HALF) of Apixaban

    Samples of plasma from participants were obtained at the following times: 0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h, relative to the single dose on Day 1 in each cross over period. Apixaban was assayed using a validated LC-MS/MS method during the period of known analyte stability. T-HALF was measured in hours (h).

    Time frame: Day 1 (0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h post dose) in Periods 1, 2 and 3

  6. Number of Participants With Clinically Significant Electrocardiogram, Vital Sign, or Physical Examination Findings

    12-lead electrocardiograms (ECGs) and Vital Signs were performed at Screening, and Day 1 of Periods 1, 2 and 3 (pre-dose and prior to NGT placement, if done). Vital signs and ECGs were also performed on Day 4 of Period 3, prior to discharge from the study. Vital signs included body temperature, respiratory rate, seated blood pressure and heart rate. Blood pressure and heart rate were measured after the participant had been seated quietly for at least 5 minutes. Participants had physical examinations on Period 1, Day 1 (pre-dose) and Day 4 of Period 3, prior to study discharge.

    Time frame: Screening, Day 1 of Periods, 1, 2, and 3, and Day 4 of Period 3

  7. Number of Participants With Marked Abnormality in Hematology, Chemistry and Urinalysis Laboratory Tests

    Participants were required to fast for at least 10 hours prior to the collection of specimens for clinical laboratory tests. Tests were performed at Screening, Day -1, and Day 4 of each period 1 - 3. Leukocyte criteria: Lower limits of normal (LLN), upper limits of normal (ULN), pre-treatment (preRX). Low Leukocytes: if value \< 0.9\*LLN, or if preRX \< LLN then use \< 0.85\* preRX. High lymphocytes: if value \> 7.500 10\^3 cells/ µL. Low neutrophils plus bands: if value \<= 1.500 10\^3 cells/µL. High creatine kinase: if value \> 1.5\* ULN. Blood in urine: if value \>= 2 plus, or if preRX \>= 1 plus then use \>= 2\*preRX.

    Time frame: Screening, Day -1, Day 4 of Periods, 1, 2, and 3

07

Results

Posted Jul 20, 2016

Participant flow

Participants were admitted to the clinical facility on the evening prior to dosing (Day -1) and remained confined to the clinic for the duration of study.

Participant flow — Overall Study
MilestoneTreatment A, Then Treatment B, Then Treatment CTreatment A, Then Treatment C, Then Treatment BTreatment B, Then Treatment A, Then Treatment CTreatment B, Then Treatment C, Then Treatment ATreatment C, Then Treatment A, Then Treatment BTreatment C, Then Treatment B, Then Treatment A
Started434343
Completed434343
Not completed000000

Outcome measures

SecondaryNumber of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs, Death

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

Time frame:
Day 1 to Day 12
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs, Death
participants5mg Apixaban Via Oral Syringe (A)5mg Apixaban Via NGT Followed by D5W (B)5 mg Apixaban Via NGT Followed by Infant Formula (C)
Discontinuation Due to AE000
SAE000
Death000
Adverse Events243
PrimaryAdjusted Geometric Mean Maximum Observed Plasma Concentration (Cmax) of Apixaban

Samples of plasma from participants were obtained at the following times: 0 hour (h) and post dose at 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h. Apixaban was assayed using a validated Liquid chromatography tandem mass spectrometry (LC-MS/MS) method during the period of known analyte stability. Maximum observed plasma concentration (Cmax) was measured in nanograms per milliliter (ng/mL).

Time frame:
Day 1 (0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h post dose) in Periods 1, 2 and 3
Reported as:
Geometric mean · ng/mL
Adjusted Geometric Mean Maximum Observed Plasma Concentration (Cmax) of Apixaban
ng/mL5mg Apixaban Via Oral Syringe (A)5mg Apixaban Via NGT Followed by D5W (B)5 mg Apixaban Via NGT Followed by Infant Formula (C)
Adjusted Geometric Mean Maximum Observed Plasma Concentration (Cmax) of Apixaban190.873 (176.032 to 206.965)181.862 (162.834 to 203.112)153.693 (140.686 to 167.904)
Statistical analysis
  • 5mg Apixaban Via Oral Syringe (A) vs 5mg Apixaban Via NGT Followed by D5W (B) · Ratio of adjusted geometric means: 0.953 · 90% CI 0.873 to 1.040
  • 5mg Apixaban Via Oral Syringe (A) vs 5 mg Apixaban Via NGT Followed by Infant Formula (C) · Ratio of adjusted geometric means: 0.805 · 90% CI 0.749 to 0.865
SecondaryMedian Time of Maximum Observed Plasma Concentration (Tmax) of Apixaban

Samples of plasma from participants were obtained at the following times: 0 hour (h), 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h, relative to the single dose on Day 1 in each cross over period. Apixaban was assayed using a validated LC-MS/MS method during the period of known analyte stability. Maximum observed plasma concentration (Tmax) was measured in hours (h).

Time frame:
Day 1 (0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h post dose) in Periods 1, 2 and 3
Reported as:
Median · h
Median Time of Maximum Observed Plasma Concentration (Tmax) of Apixaban
h5mg Apixaban Via Oral Syringe (A)5mg Apixaban Via NGT Followed by D5W (B)5 mg Apixaban Via NGT Followed by Infant Formula (C)
Median Time of Maximum Observed Plasma Concentration (Tmax) of Apixaban0.517 (0.48 to 2.00)1.000 (0.30 to 2.00)1.00 (0.48 to 2.00)
SecondaryAdjusted Geometric Mean Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of Last Quantifiable Plasma Concentration, AUC(0-T), of Apixaban

Samples of plasma from participants were obtained at the following times: 0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h, relative to the single dose on Day 1 in each cross over period. Apixaban was assayed using a validated LC-MS/MS method during the period of known analyte stability. AUC(0-T) was measured in nanograms\*hours per milliliter (ng\*h/mL).

Time frame:
Day 1 (0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h post dose) in Periods 1, 2 and 3
Reported as:
Geometric mean · ng*h/mL
Adjusted Geometric Mean Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of Last Quantifiable Plasma Concentration, AUC(0-T), of Apixaban
ng*h/mL5mg Apixaban Via Oral Syringe (A)5mg Apixaban Via NGT Followed by D5W (B)5 mg Apixaban Via NGT Followed by Infant Formula (C)
Adjusted Geometric Mean Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of Last Quantifiable Plasma Concentration, AUC(0-T), of Apixaban1269.784 (1140.000 to 1414.343)1226.339 (1064.999 to 1412.121)1166.572 (1031.549 to 1319.268)
Statistical analysis
  • 5mg Apixaban Via Oral Syringe (A) vs 5mg Apixaban Via NGT Followed by D5W (B) · Ratio of adjusted geometric means: 0.966 · 90% CI 0.924 to 1.010
  • 5mg Apixaban Via Oral Syringe (A) vs 5 mg Apixaban Via NGT Followed by Infant Formula (C) · Ratio of adjusted geometric means: 0.919 · 90% CI 0.896 to 0.942
SecondaryAdjusted Geometric Mean Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time, AUC(INF), of Apixaban

Samples of plasma from participants were obtained at the following times: 0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h, relative to the single dose on Day 1 in each cross over period. Apixaban was assayed using a validated LC-MS/MS method during the period of known analyte stability. AUC(0-INF) was measured in ng\*h/mL.

Time frame:
Day 1 (0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h post dose) in Periods 1, 2 and 3
Reported as:
Geometric mean · ng*h/mL
Adjusted Geometric Mean Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time, AUC(INF), of Apixaban
ng*h/mL5mg Apixaban Via Oral Syringe (A)5mg Apixaban Via NGT Followed by D5W (B)5 mg Apixaban Via NGT Followed by Infant Formula (C)
Adjusted Geometric Mean Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time, AUC(INF), of Apixaban1292.775 (1161.691 to 1438.650)1250.913 (1088.380 to 1437.718)1192.387 (1056.600 to 1345.624)
Statistical analysis
  • 5mg Apixaban Via Oral Syringe (A) vs 5mg Apixaban Via NGT Followed by D5W (B) · Ratio of adjusted geometric means: 0.968 · 90% CI 0.926 to 1.011
  • 5mg Apixaban Via Oral Syringe (A) vs 5 mg Apixaban Via NGT Followed by Infant Formula (C) · Ratio of adjusted geometric means: 0.922 · 90% CI 0.899 to 0.947
SecondaryMean Plasma Elimination Half-Life (T-HALF) of Apixaban

Samples of plasma from participants were obtained at the following times: 0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h, relative to the single dose on Day 1 in each cross over period. Apixaban was assayed using a validated LC-MS/MS method during the period of known analyte stability. T-HALF was measured in hours (h).

Time frame:
Day 1 (0 h, 0.25h, 0.50h, 1h, 2h, 3h, 4h, 5h, 6h, 9h, 12h, 24h, 36h, 48h, 60h, and 72h post dose) in Periods 1, 2 and 3
Reported as:
Mean · h
Mean Plasma Elimination Half-Life (T-HALF) of Apixaban
h5mg Apixaban Via Oral Syringe (A)5mg Apixaban Via NGT Followed by D5W (B)5 mg Apixaban Via NGT Followed by Infant Formula (C)
Mean Plasma Elimination Half-Life (T-HALF) of Apixaban10.5 ± 4.210.4 ± 4.510.6 ± 3.8
SecondaryNumber of Participants With Clinically Significant Electrocardiogram, Vital Sign, or Physical Examination Findings

12-lead electrocardiograms (ECGs) and Vital Signs were performed at Screening, and Day 1 of Periods 1, 2 and 3 (pre-dose and prior to NGT placement, if done). Vital signs and ECGs were also performed on Day 4 of Period 3, prior to discharge from the study. Vital signs included body temperature, respiratory rate, seated blood pressure and heart rate. Blood pressure and heart rate were measured after the participant had been seated quietly for at least 5 minutes. Participants had physical examinations on Period 1, Day 1 (pre-dose) and Day 4 of Period 3, prior to study discharge.

Time frame:
Screening, Day 1 of Periods, 1, 2, and 3, and Day 4 of Period 3
Reported as:
Number · participants
Number of Participants With Clinically Significant Electrocardiogram, Vital Sign, or Physical Examination Findings
participants5mg Apixaban Via Oral Syringe (A)5mg Apixaban Via NGT Followed by D5W (B)5 mg Apixaban Via NGT Followed by Infant Formula (C)
ECG000
Vital Signs000
Physical Examination000
SecondaryNumber of Participants With Marked Abnormality in Hematology, Chemistry and Urinalysis Laboratory Tests

Participants were required to fast for at least 10 hours prior to the collection of specimens for clinical laboratory tests. Tests were performed at Screening, Day -1, and Day 4 of each period 1 - 3. Leukocyte criteria: Lower limits of normal (LLN), upper limits of normal (ULN), pre-treatment (preRX). Low Leukocytes: if value \< 0.9\*LLN, or if preRX \< LLN then use \< 0.85\* preRX. High lymphocytes: if value \> 7.500 10\^3 cells/ µL. Low neutrophils plus bands: if value \<= 1.500 10\^3 cells/µL. High creatine kinase: if value \> 1.5\* ULN. Blood in urine: if value \>= 2 plus, or if preRX \>= 1 plus then use \>= 2\*preRX.

Time frame:
Screening, Day -1, Day 4 of Periods, 1, 2, and 3
Reported as:
Number · participants
Number of Participants With Marked Abnormality in Hematology, Chemistry and Urinalysis Laboratory Tests
participants5mg Apixaban
Low Leukocytes1
High Lymphocytes1
Low Neutrophils plus bands5
High Creatine Kinase1
Blood in Urine1

Adverse events

Collected over Day 1 to Day 12. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
5mg Apixaban Via Oral Syringe (A)—0/21 (0%)2/21 (9.5%)
5mg Apixaban Via NGT Followed by D5W (B)—0/21 (0%)4/21 (19%)
5 mg Apixaban Via NGT Followed by Infant Formula (C)—0/21 (0%)3/21 (14.3%)
Most frequent other events
Most frequent other events
Event5mg Apixaban Via Oral Syringe (A)5mg Apixaban Via NGT Followed by D5W (B)5 mg Apixaban Via NGT Followed by Infant Formula (C)
RhinorrhoeaRespiratory, thoracic and mediastinal disorders1/210/211/21
Throat IrritationRespiratory, thoracic and mediastinal disorders0/211/210/21
Abdominal PainGastrointestinal disorders1/211/210/21
HeadacheNervous system disorders1/211/210/21
Eyelid OedemaEye disorders0/211/210/21
Arthropod biteInjury, poisoning and procedural complications0/210/211/21
Pain in extremityMusculoskeletal and connective tissue disorders0/210/211/21
DysmenorrhoeaReproductive system and breast disorders0/211/210/21

Baseline characteristics

All participants who received study drug were analyzed.

Age, Continuous
Age, Continuous(years)5mg Apixaban
Mean33 ± 6.7
Sex: Female, Male
Sex: Female, Male(Participants)5mg Apixaban
Female8
Male13
Region of Enrollment
Region of Enrollment(participants)5mg Apixaban
United States21
08

Study locations

1 site
  • Parexel Baltimore Early Phase Clinical Unit
    Baltimore, Maryland 21225, United States
09

References and documents

Publications

  • Song Y, Wang X, Perlstein I, Wang J, Badawy S, Frost C, LaCreta F. Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects. Clin Ther. 2015 Aug;37(8):1703-12. doi: 10.1016/j.clinthera.2015.05.497. Epub 2015 Jul 15. PubMed 26188837 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2016, 4 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2014
First posted
Jan 13, 2014
Start
Jul 2011
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Results first posted
Jul 20, 2016
Last update
Jul 20, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02034578
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Jan 13, 2014
Start date
Jul 2011
Primary completion
Aug 2011
Completion
Aug 2011
Results posted
Jul 20, 2016
Last update
Jul 20, 2016

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion